D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control Title:The Optimization of the Current ININ Method of Lu-177-DOTA-HYNIC-iPSMA (e-poster) Presenter: Yehia Omar, Misr Radiology Center, Cairo, EGYPT Presentation ID: EP-0880 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn. Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[2] by the Australian Therapeutic Goods Administration (TGA),[3] and by Health Canada.[4]Telix is also progressing Marketing Authorisation Applications for 68Ga-PSMA-11 in the United Kingdom and the European Union.[5] Telix Investor Relations Ms.Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] Legal Notices This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved). [1] A collaboration with the Oncidium Foundation. [2]Telix ASX disclosure 20 December 2021. [3]Telix ASX disclosure 2 November 2021. [4]Telix ASX disclosure 14 October 2022. [5]Telix ASX disclosure 3 April 2023. "/> D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control Title:The Optimization of the Current ININ Method of Lu-177-DOTA-HYNIC-iPSMA (e-poster) Presenter: Yehia Omar, Misr Radiology Center, Cairo, EGYPT Presentation ID: EP-0880 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn. Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA), [2] by the Australian Therapeutic Goods Administration (TGA), [3] and by Health Canada.[4]Telix is also progressing Marketing Authorisation Applications for 68Ga-PSMA-11 in the United Kingdom and the European Union.[5] Telix Investor Relations Ms.Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] Legal Notices This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved). [1] A collaboration with the Oncidium Foundation. [2]Telix ASX disclosure 20 December 2021. [3]Telix ASX disclosure 2 November 2021. [4]Telix ASX disclosure 14 October 2022. [5]Telix ASX disclosure 3 April 2023. "/> D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control Title:The Optimization of the Current ININ Method of Lu-177-DOTA-HYNIC-iPSMA (e-poster) Presenter: Yehia Omar, Misr Radiology Center, Cairo, EGYPT Presentation ID: EP-0880 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn. Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[2] by the Australian Therapeutic Goods Administration (TGA),[3] and by Health Canada.[4]Telix is also progressing Marketing Authorisation Applications for 68Ga-PSMA-11 in the United Kingdom and the European Union.[5] Telix Investor Relations Ms.Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] Legal Notices This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved). [1] A collaboration with the Oncidium Foundation. [2]Telix ASX disclosure 20 December 2021. [3]Telix ASX disclosure 2 November 2021. [4]Telix ASX disclosure 14 October 2022. [5]Telix ASX disclosure 3 April 2023. " /> D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control Title:The Optimization of the Current ININ Method of Lu-177-DOTA-HYNIC-iPSMA (e-poster) Presenter: Yehia Omar, Misr Radiology Center, Cairo, EGYPT Presentation ID: EP-0880 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn. Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[2] by the Australian Therapeutic Goods Administration (TGA),[3] and by Health Canada.[4]Telix is also progressing Marketing Authorisation Applications for 68Ga-PSMA-11 in the United Kingdom and the European Union.[5] Telix Investor Relations Ms.Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] Legal Notices This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved). [1] A collaboration with the Oncidium Foundation. [2]Telix ASX disclosure 20 December 2021. [3]Telix ASX disclosure 2 November 2021. [4]Telix ASX disclosure 14 October 2022. [5]Telix ASX disclosure 3 April 2023. " />
Sun, 06 Apr 2025

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.

More Information
null in null

International

Section
Boeing CEO to face lawmakers amid safety concerns and public scrutiny
Boeing made 'serious missteps' but is changing, CEO tells Congress

WASHINGTON, D.C.: Boeing's top executive faced lawmakers on April 2 as the company worked to repair its reputation following a string...

Over 1,000 firefighters train at Arizona Wildfire Academy
On heels of dry winter, firefighters in US brace for wildfires

PRESCOTT, Arizona: More than 1,000 firefighters and fire managers recently trained at the annual wildfire academy in Arizona. They...

Ex-NYC fire chief sentenced to nearly 2 years for bribery scheme
Ex-FDNY chief gets nearly 2 years in federal prison for taking bribes

NEW YORK CITY, New York: A former New York City Fire Department chief has been sentenced to nearly two years in federal prison for...

Rail giant wants help to pay Ohio-Pennsylvania derailment settlement
Trial to decide $600 million settlement in Norfolk Southern derailment

EAST PALESTINE, Ohio: Norfolk Southern wants two other companies to help pay for the $600 million settlement it agreed to after a major...

Wildfire in eastern Sierra burns 1,000 acres, triggers evacuations
Growing eastern California wildfire compels evacuations, Cal Fire says

BISHOP, California: A fast-growing wildfire in California's Eastern Sierra region has burned 1,000 acres and forced people to leave...

Passenger plane, military jet avoid collision in Washington D.C.
Passenger plane, Air Force jet avoid near collision in Washington D.C.

WASHINGTON, D.C.: A U.S. passenger plane getting ready to take off and a military jet coming in were told to change course to avoid...

Business

Section
BOC Aviation expands global fleet with major Airbus, Boeing orders
Lessor BOC Aviation to buy 120 Airbus, Boeing jets to grow fleet

SINGAPORE: BOC Aviation is betting big on the future of air travel, placing major orders with both Airbus and Boeing as it moves to...

Ghibli-inspired AI art boosts ChatGPT usage
ChatGPT usage hits record after rollout of Ghibli feature

SAN FRANCISCO, California: A wave of Ghibli-inspired AI artwork has sent ChatGPT usage skyrocketing, as users have embraced the image-generation...

Virgin Atlantic sees dip in US-UK travel amid economic uncertainty
Virgin Atlantic reports slowdown in US to UK travel

LONDON, U.K.: Virgin Atlantic is seeing signs of cooling demand from U.S. travelers heading to the UK, a shift that comes after a strong...

Wall Street sheds nearly 6% more as tariffs continue to take toll
U.S. stocks continue plunging, Dow Jones loses 2,231 points

NEW YORK, New York - The rout in U.,S. and global stock markets continued and even heightened on Friday, as investors around the world...

FCC investigates Disney, ABC amid diversity policy scrutiny
FCC opening probe into diversity practices at Disney and ABC

WASHINGTON/LOS ANGELES: The U.S. government is intensifying scrutiny of corporate diversity policies, with Disney and ABC now under...

US states compete for role in smaller next-gen nuclear power
Small, cheap nuclear reactors see US states racing to attract industry

HARRISBURG, Pennsylvania: New, cheaper nuclear power is on the way, and U.S. states are competing to build and supply the next generation...

Movie Review